Literature DB >> 21373232

An unusual cause of elevated values on liver function tests in a liver transplant patient.

Ankur Jain, Amandeep Sahota, Najeeb S Alshak, Jim K Tung.   

Abstract

Entities:  

Year:  2009        PMID： 21373232      PMCID： PMC3034433          DOI： 10.7812/TPP/08-056

Source DB:  PubMed          Journal:  Perm J        ISSN： 1552-5767


× No keyword cloud information.
  13 in total

1.  Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.

Authors:  A S Yu; J M Vierling; S D Colquhoun; W S Arnaout; C K Chan; E Khanafshar; S A Geller; W S Nichols; T L Fong
Journal:  Liver Transpl       Date:  2001-06       Impact factor: 5.799

2.  Incidence and features of liver disease in patients on chronic hemodialysis.

Authors:  M Bruguera; L Vidal; J M Sanchez-Tapias; J Costa; L Revert; J Rodes
Journal:  J Clin Gastroenterol       Date:  1990-06       Impact factor: 3.062

3.  Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.

Authors:  S F Dodson; C A Bonham; D A Geller; T V Cacciarelli; J Rakela; J J Fung
Journal:  Transplantation       Date:  1999-10-15       Impact factor: 4.939

4.  Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.

Authors:  Yaw-Sen Chen; Chih-Chi Wang; Vanessa H de Villa; Shih-Hor Wang; Yu-Fan Cheng; Tung-Liang Huang; Bruno Jawan; King-Wah Chiu; Chao-Long Chen
Journal:  Clin Transplant       Date:  2002-12       Impact factor: 2.863

5.  A randomized controlled trial of lamivudine to treat acute hepatitis B.

Authors:  M Kumar; S Satapathy; R Monga; K Das; S Hissar; C Pande; B C Sharma; S K Sarin
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

Review 6.  Hepatitis B: global importance and need for control.

Authors:  J E Maynard
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

7.  De novo and apparent de novo hepatitis B virus infection after liver transplantation.

Authors:  B Roche; D Samuel; M Gigou; C Feray; V Virot; L Schmets; M F David; J L Arulnaden; A Bismuth; M Reynes; H Bismuth
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

Review 8.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

9.  The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors.

Authors:  M E Wachs; W J Amend; N L Ascher; P N Bretan; J Emond; J R Lake; J S Melzer; J P Roberts; S J Tomlanovich; F Vincenti
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

10.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies.

Authors:  M J Alter; S C Hadler; H S Margolis; W J Alexander; P Y Hu; F N Judson; A Mares; J K Miller; L A Moyer
Journal:  JAMA       Date:  1990-03-02       Impact factor: 56.272
View more
  1 in total

1.  Liver Function Enzymes are Potential Predictive Markers for Kidney Allograft Dysfunction.

Authors:  Alakesh Bera; Eric Russ; Rahul M Jindal; Maura A Watson; Robert Nee; Ofer Eidelman; John Karaian; Harvey B Pollard; Meera Srivastava
Journal:  Adv J Urol Nephrol       Date:  2020-03-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.